The incidence of ovarian cancer is > 50% in women aged greater than or
equal to 65 years. Histology and stage at diagnosis are both related
to age, which appears to be an independent prognostic factor for survi
val in univariate analysis. Special conditions relating to the treatme
nt of elderly women with ovarian cancer and the drugs active in this d
isease are discussed. New, less toxic combinations of paclitaxel (Taxo
l(R), Bristol-Myers Squibb Company) and platinum-derived compounds app
ear to be promising.